TL;DR
Isolated in 1977. Gene, receptor, and mechanism are all still missing.
What: Nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Monnier and Schoenenberger isolated it in 1977 from rabbit cerebral venous blood during electrically induced slow-wave sleep.
Does: Crosses the blood-brain barrier. Nudges slow-wave sleep in some trials, not others. Shows opiate-receptor-adjacent activity without the classical opiate profile. Four decades in, no receptor cloned.
Evidence: Dick/Tissot 1984 (PMIDs 6548969, 6328354) reported 97% opiate and 87% alcohol withdrawal relief in 107 uncontrolled patients. Kaeser 1992 (PMID 1299794) double-blind: insomnia benefit wasn't major. Kastin 2003 (PMID 12603834) titled his review "a still unresolved riddle."
Used by: Community users at 100–500 mcg SubQ pre-bed for sleep and recovery. Historical Swiss and Eastern European clinical use for withdrawal has lapsed.
Verdict: Real human signal in withdrawal. Underwhelming in insomnia. No gene, no receptor, no modern Phase 2. The neuroscience field parked it.
What It Is
Delta Sleep-Inducing Peptide (DSIP) is a nine-amino-acid nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter code WAGGDASGE), molecular weight 848.8 Da. It was isolated in 1977 by the Swiss group of Marcel Monnier and Guido Schoenenberger at the Institute of Physiology, University of Basel, from cerebral venous blood of rabbits subjected to electrical stimulation of the intralaminar thalamic nuclei that induced slow-wave (delta) sleep. The isolation was based on the hypothesis that sleep-promoting factors accumulate in brain blood during electrically induced sleep and could be recovered by bioassay-guided fractionation — an approach that also produced the related "sleep factor" research of Pappenheimer in the 1970s.
Unlike most neuropeptides on this site, DSIP's biosynthetic origin remains unclear. Despite extensive work over four decades, no human DSIP gene has been definitively cloned, and no specific high-affinity DSIP receptor has been identified. BLAST searches align the DSIP sequence with a hypothetical Amycolatopsis coloradensis bacterial protein, raising the speculative possibility of a bacterial rather than eukaryotic biosynthetic origin — although this has not been experimentally confirmed. The mechanistic underdetermination is the defining feature of DSIP biology in 2026: the peptide demonstrably does something in animals and humans, but four decades have not produced the molecular-target clarity that normally accompanies a serious drug-development program.
DSIP has several unusual physiochemical properties for a peptide. It is small (9 amino acids), crosses the blood-brain barrier through mechanisms that include saturable transport and possible direct passive permeation, and is absorbed orally and through the nasal mucosa — extremely unusual for a short linear peptide. These properties have allowed DSIP human research to employ IV, SubQ, oral, and intranasal routes, whereas most research peptides are restricted to injection.
DSIP is supplied exclusively as a synthetic peptide — native tissue isolation is not a practical supply route. Synthesis is straightforward given the short linear sequence with no disulfide bonds or unusual modifications. Research-reagent vendors (Bachem, Anaspec, Genscript, and community-grade suppliers) supply ≥98% purity material. There is no FDA-approved DSIP therapeutic; historical use in Swiss and Eastern European clinical settings (alcohol / opiate withdrawal) occurred under national-level regulatory frameworks that have since largely lapsed.
Mechanism of Action
DSIP's mechanism remains one of the most genuinely unresolved questions in neuropeptide pharmacology. The published data are inconsistent across laboratories and assay systems, reflecting either multiple overlapping mechanisms or methodological artifacts. Observations that recur across independent groups include:
- Slow-wave sleep promotion (context-dependent) — Original Monnier / Schoenenberger animal work showed DSIP administration increases delta-wave activity on EEG. Human studies replicate this in some protocols and not others; effect size is modest when present. The variability has been attributed to circadian timing of administration, species differences, and dose-response nonlinearities.
- REM sleep modulation — DSIP can increase REM sleep proportion under some conditions and decrease it under others; net effect varies by circadian timing of dose, underlying sleep state of the subject, and specific analog studied (native DSIP vs more stable modified analogs).
- Opiate-receptor agonist-like activity — The most clinically translated finding. Tissot and the Swiss group demonstrated that DSIP injection into the bulbo-mesencephalo-thalamic recruiting system produces slow-wave sleep similar to morphine, alcohol, and pentobarbital. This suggested opiate-receptor partial agonism, supporting the clinical trial use of DSIP in alcohol and opiate withdrawal. The receptor interaction is not a clean μ-opioid agonism (DSIP does not produce the classical opiate high or analgesia profile), possibly involving partial or allosteric engagement at opioid receptors or indirect pathways.
- NMDA receptor modulation (animal data) — Some rodent studies suggest DSIP acts through NMDA receptor systems centrally, modulating glutamatergic tone. Effect direction is bidirectional depending on context.
- α1-adrenergic stimulation of acetyltransferase — In rats, DSIP stimulated acetyltransferase activity through α1-adrenergic receptors. This is one specific identified receptor interaction, although its physiological significance for sleep or other functions is unclear.
- HPA axis modulation — Animal studies suggest DSIP affects corticotropin-releasing hormone (CRH), ACTH, and cortisol regulation, potentially providing a stress-buffering effect. Clinical human data are limited.
- Somatoliberin (GHRH) stimulation — Some research suggests DSIP promotes growth-hormone-releasing hormone release, which would secondarily support slow-wave sleep (GHRH is itself a slow-wave sleep promoter). The effect is indirect and incompletely characterized.
- Blood-brain barrier penetration — DSIP crosses the BBB via saturable peptide transport system (PTS-1) that also transports several other neuropeptides. This allows central effects after peripheral administration.
- Oral bioavailability — Caco-2 cell monolayer studies show DSIP is transported and metabolized by intestinal epithelial cells; intact peptide reaches systemic circulation after oral administration — unusual for a 9-mer peptide. This supports historical oral-formulation human trials.
- Degradation / half-life — Plasma half-life is short (reports vary 5–15 minutes). Modified analogs with increased stability have been developed for research use.
- No cloned receptor — Despite four decades of work, no specific high-affinity DSIP receptor has been cloned or characterized. Actions appear to be polymodal, engaging multiple receptor systems rather than a single selective target.
What the Research Shows
DSIP research falls into two distinct eras: an active 1970s–80s period producing the foundational human trials, and a quieter post-1990s period of scattered mechanistic studies. Major published findings:
- Original isolation — Monnier M, Dudás B, Prochiantz A. Sleep-inducing factor: a neuropeptide? Nature. 1977;268(5616):152-153. The foundational paper establishing DSIP as a distinct sleep-associated neuropeptide from rabbit cerebral venous blood during induced slow-wave sleep.
- Chronic insomnia IV pilot — Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP on disturbed human sleep. Experientia. 1981;37(8):876-878. PMID 7028502. 6 middle-aged chronic insomniacs received 25 nmol/kg IV DSIP. Longer sleep duration, higher sleep quality with fewer interruptions, slightly more REM sleep, no daytime sedation. Small N; suggestive but not definitive.
- Chronic insomnia short-term trial — Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987;7(2):105-110. PMID 3583493.
- Chronic insomnia double-blind RCT — Kaeser HE, Mouret J, Helmert DS. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Eur Neurol. 1992;32(Suppl 1):22-27. PMID 1299794. 16 patients; 3rd-5th nights received either 25 nmol/kg IV DSIP or glucose placebo. Results: higher sleep efficiency and shorter sleep latency with DSIP vs placebo, but effects "weak and in part could be due to an incidental change in the placebo group." Conclusion: "short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit." This negative double-blind result substantially deflated enthusiasm for the sleep indication.
- Alcohol / opiate withdrawal trials — Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-371. PMID 6548969. 107 inpatients (47 alcohol, 60 opiate) received IV DSIP. Clinical symptoms disappeared or improved rapidly in 97% of opiate and 87% of alcohol patients. PMID 6328354 reports similar success in 67 patients (28 alcohol, 39 opiate) with 48 of 49 evaluable patients showing benefit. These studies were uncontrolled but the response rate was notable.
- Chronic pain pilot — Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-385. Reported symptomatic improvement in chronic pain; uncontrolled design.
- MDD (major depressive disorder) association — Multiple observational studies examined DSIP plasma and CSF levels in MDD patients; findings contradictory (some show higher, some lower than controls). No clear diagnostic or therapeutic conclusion emerged.
- Narcolepsy — Some reports of DSIP normalizing sleep patterns in narcolepsy, although evidence is case-series level and not Phase 2/3 validated.
- HPA axis and stress — Rodent studies (Salieva 1992) suggest DSIP increases hypothalamic substance P and increases stress-resistance. Human translation minimal.
- Kastin review 2003 — Kastin AJ, Akerstrom V. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2003;84(6):1116-1122. The defining 21st-century review — titled "unresolved riddle" for a reason. Kastin (who was instrumental in BBB-penetration research for many peptides) summarized the field's state: real pharmacology, real cross-BBB transport, real human-trial signals, but no receptor, no gene, no clean mechanistic model.
Critical Context — Mechanistic Underdetermination
DSIP is unusual for a "research peptide" in that its historical clinical-trial record is more robust than its modern mechanistic understanding. The 1970s–80s human trials produced real signals — particularly in opiate/alcohol withdrawal — but the field largely moved on after the 1990s when receptor cloning and molecular pharmacology became the dominant standard of evidence and DSIP could not pass those tests. Modern community use is essentially reviving a pharmacology that the mainstream neuroscience field parked. Occasional interesting preclinical papers emerge (HPA axis, substance P, neuroprotection) but no sustained program has advanced it toward FDA approval.
Human Data
DSIP has a moderate human trial record concentrated in 1970s–80s Swiss and Western European clinical research:
- Chronic insomnia trials (Swiss group) — Multiple small trials in middle-aged chronic insomniacs at 25 nmol/kg IV DSIP. Net result: mixed — acute signal of improved sleep continuity in some studies, equivocal double-blind result in others. The 1992 Kaeser double-blind concluded short-term DSIP "not likely to be of major therapeutic benefit" for chronic insomnia.
- Alcohol withdrawal trials — 87% symptom alleviation reported in uncontrolled IV DSIP administration during acute alcohol withdrawal. Findings from Dick/Tissot 1984 cohort of 107 patients.
- Opiate withdrawal trials — 97% symptom alleviation reported in uncontrolled IV DSIP administration during acute opiate withdrawal. Same Dick/Tissot 1984 cohort plus follow-up. Headaches reported as the most common adverse effect.
- Chronic pain pilot — Larbig et al. 1984 pilot in patients with chronic, pronounced pain episodes reported improvement. Uncontrolled.
- Sleep apnea / narcolepsy case series — Various small case-series reports of DSIP in narcolepsy and sleep-apnea-associated sleep disturbance. Case-series evidence level only.
- Observational DSIP-plasma-level studies — Contradictory findings in depression, sleep apnea, narcolepsy; no consistent biomarker relationship established.
- No modern Phase 2/3 trials — No DSIP trials registered on ClinicalTrials.gov as active or recruiting. The compound has not received modern pharmaceutical development investment.
Dosing from the Literature
DSIP dosing in the published human literature is anchored to the Swiss clinical trial programs of the 1970s–80s, primarily IV administration in clinical settings. Community use has extrapolated to SubQ and intranasal routes without controlled human data at those protocols.
| Context | Dose | Route | Notes |
|---|
| Chronic insomnia (Schneider-Helmert / Kaeser) | 25 nmol/kg (~21 μg/kg) | IV single dose | The canonical clinical dose from the Swiss trials. |
| Alcohol / opiate withdrawal (Dick / Tissot) | 25 nmol/kg | IV single dose | Same dose; repeated as needed during withdrawal course. |
| 70 kg adult equivalent | ~1.5 mg IV | — | Clinical dose in absolute terms. |
| Community SubQ protocol | 100–500 mcg | SubQ pre-bed | Well below clinical dose equivalent. No controlled data. |
| Community intranasal protocol | 100–500 mcg | Intranasal | Leverages DSIP's documented intranasal/oral bioavailability. Less common than SubQ. |
| Oral | ~500 μg – 2 mg | Oral capsule | Rarely used in community practice despite historical oral trials. |
| Cycle length (community) | Nightly × 4–8 weeks | — | No formal cycling requirement; community practice is variable. |
Dosing Disclaimer
DSIP's published clinical dosing is IV in a medical setting. Community SubQ and intranasal doses at 100–500 mcg are not equivalent to the clinical IV protocol and have no controlled efficacy or safety data at that route. DSIP is not FDA-approved for any indication. For insomnia, the 1992 double-blind Kaeser result suggests DSIP is unlikely to produce major therapeutic benefit — modern evidence-based sleep therapeutics (cognitive behavioral therapy for insomnia, FDA-approved hypnotics, melatonin) should be considered first-line.
Reconstitution & Storage
DSIP is supplied for research use as a synthetic lyophilized peptide. The 9-amino-acid linear sequence is straightforward to synthesize and supply by many research-reagent vendors:
| Form | Typical Quantity | Reconstitution | Storage |
|---|
| Lyophilized vial (research-grade) | 2–5 mg | BAC water or sterile water | −20°C lyophilized; 2–8°C reconstituted (use within 28 days) |
| Intranasal spray (community) | 5 mg / 2 mL | Pre-formulated aqueous | Refrigerate; use within 30 days |
| Modified analog (research) | Custom | Per protocol | Enhanced stability over native DSIP |
- Reconstitution — For a 2 mg vial, add 2 mL BAC water for a 1,000 mcg/mL concentration; 200 mcg dose = 0.20 mL (20 units on a U-100 insulin syringe).
- Stability — DSIP is relatively stable in solution compared to longer peptides but still benefits from cold storage. Keep reconstituted solution at 2–8°C and use within 28 days.
- Storage — Lyophilized vials stable at −20°C for 2+ years. Refrigerated reconstituted solution for up to 28 days.
- Inspection — Clear, colorless reconstituted solution. Discard if cloudy, discolored, or showing visible particulate.
→ Use the Kalios Dosing Calculator for vial conversions
Side Effects & Risks
Important
DSIP has a benign 1970s safety record and essentially no modern pharmacovigilance. Headache is the most reported effect; dependence and tolerance aren't documented. For chronic insomnia, CBT-I and approved hypnotics clear a higher bar. Talk to someone licensed before deciding whether this adds anything beyond those.
DSIP has a historically benign safety profile from the 1970s–80s clinical trials, although modern characterization is limited:
- Headache — Most commonly reported side effect in historical trials. Self-limiting.
- Mild injection-site reactions (SubQ) — Uncommon; typically mild redness or tenderness.
- Sedation — Dose-related drowsiness is the intended effect for sleep applications; at excessive doses may produce daytime grogginess. Not a life-threatening effect.
- No dependence / tolerance signal — Unlike benzodiazepines and Z-drugs, DSIP has not shown tolerance development or withdrawal phenomena in the published clinical record. This is mechanistically consistent with the non-GABA mechanism.
- Paradoxical stimulation (occasional) — Schneider-Helmert 1981 reported slight arousing effect in the first hour after injection before sleep-promoting effect in the second hour. Not consistent across subjects.
- Respiratory depression — Not documented. Unlike opiates proper, DSIP's opiate-receptor-adjacent activity does not produce classical respiratory depression.
- Drug interactions — Limited characterization. Theoretical concerns with concurrent opioid use (possible attenuation of opioid-receptor-mediated effects), MAO inhibitors, and other CNS depressants.
- Pregnancy and lactation — Not studied; avoid.
- Pediatric — Not studied; not appropriate.
- Long-term safety — Essentially uncharacterized in modern pharmacovigilance terms.
- Sourcing / purity — As a research-only synthetic peptide, DSIP quality varies between vendors. Independent third-party Certificate of Analysis (HPLC purity ≥98%, mass-spec confirmation) is the practical floor for due diligence.
Bloodwork & Monitoring
No established monitoring protocol exists. For research awareness:
- Baseline CMP and CBC — Standard pre-treatment chemistry.
- Sleep tracking — For sleep indications, subjective sleep quality logs and objective wearable / polysomnography-based tracking (sleep stages, total sleep time, sleep efficiency, WASO).
- Mood / anxiety tracking — Standardized instruments (PHQ-9, GAD-7) baseline and mid-cycle given DSIP's reported CNS effects.
- Cortisol / HPA markers — For research contexts where DSIP's stress-buffering properties are of interest: AM / PM salivary cortisol, DHEA-S.
Commonly Stacked With
Community stacking with DSIP is typically in a sleep / recovery context:
Melatonin (oral, 0.3–3 mg)
Endogenous circadian-rhythm sleep regulator. Mechanistically distinct from DSIP's slow-wave-sleep signal. Commonly co-administered pre-bed. Low-risk, broadly available as OTC dietary supplement.
Magnesium glycinate / threonate (300–400 mg)
Evening magnesium supports GABA-ergic tone and muscle relaxation. Complementary to DSIP's central sleep-promoting effect via a different pathway.
Russian anxiolytic tuftsin-derived intranasal peptide. Occasionally paired with DSIP in sleep/anxiety community protocols. Both small BBB-penetrant peptides.
Glycine (3 g oral pre-bed)
Inhibitory amino acid neurotransmitter; small human trials support modest sleep-quality improvement. Low-cost, evidence-based sleep adjunct independent of DSIP.
Khavinson tetrapeptide with proposed pineal-gland / circadian-rhythm effects. Conceptually complementary to DSIP in longevity-plus-sleep community protocols.
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
DSIP is not approved by the FDA, EMA, or any other regulator as a pharmaceutical for any indication. Historical use in Swiss and Eastern European clinical settings for alcohol / opiate withdrawal occurred under national regulatory frameworks that have since largely lapsed; no current approved DSIP product exists.
DSIP is not on the FDA Category 2 Bulk Drug Substances list and is therefore not part of HHS Secretary Robert F. Kennedy Jr.'s February 2026 reclassification announcement. As a short neuropeptide with no approved reference product and no active investigational therapeutic program, it falls outside the standard 503A compounding pathway. U.S. compounding pharmacies cannot legally compound DSIP under current FDA rules.
DSIP is not specifically named on the WADA Prohibited List. Its mechanism (unclear but CNS-modulatory) does not fit cleanly under current S-classes; competitive athletes should consult their sport-specific federation given the conservative-interpretation umbrella categories.
Internationally, DSIP has no approved pharmaceutical status in any jurisdiction as of April 2026. It exists exclusively as a research reagent.
Cost & Access
DSIP is not approved for human use. It is available through research suppliers for laboratory research purposes only.
U.S. compounding pharmacies cannot legally compound DSIP under current FDA rules — there is no FDA-approved reference product, no active investigational therapeutic program, and DSIP is not a recognized 503A bulk ingredient. Synthetic peptide for research is supplied by reagent vendors (Bachem, Anaspec, Genscript, and community-grade suppliers). Independent third-party Certificate of Analysis (HPLC purity ≥98%, mass-spec confirmation) is standard.
DSIP is not currently among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement. As a short neuropeptide without an approved reference product and no investigational program, it is unlikely to enter the standard FDA pathway absent a sponsor advancing it through formal IND-enabling toxicology and Phase 1 safety studies — an unlikely prospect given four decades of mechanistic uncertainty and the absence of contemporary pharmaceutical development interest.
Estimated pricing as of April 2026. Actual costs vary by provider, location, and prescription status. Kalios does not sell compounds.
Related Compounds
Short neuropeptides that share DSIP's BBB-penetrant, sleep-or-anxiety-adjacent niche.
Posterior pituitary nonapeptide. Pair-bonding, lactation, and social-cognition hormone.
Vasoactive intestinal peptide. Neuropeptide with anti-inflammatory, immunomodulatory, and neurotrophic activity.
N-acetylated selank analogue with longer duration and smoother anxiolytic profile.
ACTH(4-10) heptapeptide analogue. Russian nootropic with BDNF-upregulating and neuroprotective activity.
Key References
- Monnier M, Dudás B, Prochiantz A. Sleep-inducing factor: a neuropeptide? Nature. 1977;268(5616):152-153. (Foundational isolation paper.)
- Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981;37(8):876-878. PMID: 7028502.
- Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987;7(2):105-110. PMID: 3583493.
- Kaeser HE, Mouret J, Helmert DS. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Eur Neurol. 1992;32(Suppl 1):22-27. PMID: 1299794. (Double-blind negative/marginal result for chronic insomnia.)
- Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341-345. PMID: 6895513.
- Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-371. PMID: 6548969. (The 107-patient alcohol/opiate withdrawal study.)
- Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Psychoneuroendocrinology. 1984;9(1):83-89. PMID: 6328354.
- Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-385.
- Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206. PMID: 6669003.
- Kastin AJ, Akerstrom V. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2003;84(6):1116-1122. PMID: 12603834. (The defining modern review — "unresolved riddle" captures the field's state.)
- Vgontzas AN, Friedman TC, Chrousos GP, Bixler EO, Vela-Bueno A, Kales A. Delta sleep-inducing peptide in normal humans and in patients with sleep apnea and narcolepsy. J Sleep Res. 1995;4(S1):224-229. (Observational peptide-level study.)
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187. PMID: 3550841. (Classic review of the 1970s–80s data.)
- Graf MV, Kastin AJ, Schoenenberger GA. Delta sleep-inducing peptide in spontaneously hypertensive rats. Peptides. 1985;6(6):1043-1046.
- Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids. 2006;31(3):251-272. PMID: 17039418. (Context for DSIP's proposed substance P / stress-response mechanism.)
- Salieva RM, Ivanov DS, Lastochkina NA. Delta sleep-inducing peptide as a factor increasing the content of substance P in the hypothalamus and the resistance of rats to emotional stress. Neurosci Behav Physiol. 1992;22(4):275-279. (Stress-resistance rodent paper.)
- Banks WA, Kastin AJ. Passage of delta sleep-inducing peptide (DSIP) across the blood-cerebrospinal fluid barrier. Peptides. 1985;6(1):71-75. (BBB-penetration characterization.)
- Cadelis G, Bove P, Mondon K, Albaret JM. Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers. (Caco-2 oral-absorption paper.)
- Graf MV, Saegesser B, Schoenenberger GA. Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. (Stability reference.)
- Riou F, Cespuglio R, Jouvet M. Endogenous peptides and sleep in the rat. III. The hypnogenic properties of vasoactive intestinal peptide. Neuropeptides. 1982;2(5):265-277. (Context for sleep-peptide field.)
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a sleep-inducing agent or a universal homeostasis regulator? Zh Evol Biokhim Fiziol. 2006;42(1):3-10. (Russian-language review, English abstract — recent perspective on DSIP's mechanism and role.)
Last updated: April 2026 | Profile authored by Kalios Peptides research team